Bristol – Confidence in Concept 2019
Lead Research Organisation:
University of Bristol
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
People |
ORCID iD |
| Jeremy Tavare (Principal Investigator) |
Publications
Lightman SL
(2024)
Clinical Endocrinology-Time for a Reset?
in Journal of the Endocrine Society
| Description | Project Grant |
| Amount | £215,000 (GBP) |
| Organisation | Diabetes UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2021 |
| End | 04/2023 |
| Description | Technology Development Grant |
| Amount | £925,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2021 |
| End | 10/2023 |
| Description | The Investigation of Particulate Respiratory Matter to Inform Guidance for the Safe Distancing of Performers in a COVID-19 Pandemic (PERFORM-2) |
| Amount | £435,600 (GBP) |
| Funding ID | EP/V050516/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 12/2021 |
| Title | MOLECULAR DEGRADERS FOR THE TREATMENT OF IGA NEPHROPATHY |
| Description | The present invention the invention concerns bifunctional compounds of Formula (I) A-T-L1-AG, Formula (II) A-L1-Con(L2-AG)n or Formula (III) Ak ´-Th-L3 ii-AGj' wherein A is a protein that binds to the hinge region of galactose deficient IgA1 antibodies or a protein that binds to autoantibodies of galactose deficient IgA antibodies and AG is an asiaglycoprotein receptor binding moiety (ASGPR binding moiety). L1, Con and L2 are part of a linker between A and AG. The A has the ability to bind to antibodies that are a cause of IgA nephropathy and the asiaglycoprotein receptor binding moiety binds to hepatic cells thereby initiating endocytosis and removal of the antibodies that are a cause of IgA nephropathy from the blood stream. |
| IP Reference | WO2025035052 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2025 |
| Licensed | Commercial In Confidence |
| Title | VEGFC gene manipulation to protect from diabetic nephropathy |
| Description | VEGFC gene manipulation to protect from diabetic nephropathy |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | Commercial In Confidence |
| Impact | Under option to commercial entity |